Neurology Xagena
The aim of the study was to determine the association between beta-blocker or statin drug use and the future risk of symptomatic intracranial hemorrhage or persistent / progressive focal neurological deficit from cerebral cavernous malformations ( CCM ).
The population-based Scottish Audit of Intracranial Vascular Malformations has prospectively identified adults resident in Scotland first diagnosed with cerebral cavernous malformations during 1999 to 2003 or 2006 to 2010.
Researchers have compared the association between beta-blocker or statin drug use after first presentation and the occurrence of new intracranial hemorrhage or persistent / progressive focal neurological deficit due to cerebral cavernous malformations for up to 15 years of prospective follow-up.
Sixty-three ( 21% ) of 300 adults have used beta-blockers ( 27/63 [ 43% ] used Propranolol ), and 73 ( 24% ) used statin drugs over 3634 person-years of follow-up.
At baseline, the only statistically significant imbalances in prespecified potential confounders were age by statin use and intracranial hemorrhage at presentation by beta-blocker use.
Beta-blocker use was associated with a lower risk of new intracranial hemorrhage or persistent / progressive focal neurological deficit ( adjusted hazard ratio, aHR=0.09 [ 95% CI, 0.01-0.66 ]; P=0.018 ).
Statin use was associated with a nonsignificant lower risk of intracranial hemorrhage or persistent / progressive focal neurological deficit ( aHR=0.37 [ 95% CI, 0.01-1.07 ]; P=0.067 ).
In conclusion, beta-blocker, but not statin, use was associated with a lower risk of intracranial hemorrhage or persistent/progressive focal neurological deficit in patients with cerebral cavernous malformations. ( Xagena )
Zuurbier Sm et al, Stroke 2022; 53: 2521-2527
XagenaMedicine_2022
